EDIT logo

EDITAS MEDICINE INC

EDITNASDAQ
🏆 #3147 by market capEarnings Nov 9US Equity
$382.63▲ $1.15 (+0.30%)
Simulated price
🔔
Track EDIT
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.3%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$396M
Small Cap
📈Revenue Growth (YoY)
+25.4%
High Growth
📊Gross Margin
56.9%
Healthy
💵FCF Margin
-256.5%
Thin
⚖️P/S Ratio
8.4x
Elevated
Otter Score
56
Weak
No chart data available for EDIT.

Trading Snapshot

Day Range
$380.14 – $387.65
52-Week Range
$1.66 – $4.54
Volume
$2.80B
Avg Volume
$2.52B
Shares Outstanding
153.5M
Next Earnings
Nov 23, 2026

Fundamentals Snapshot

Annual Revenue
$41M
Last Q Revenue
$12M
P/E Ratio
-3.5
P/S Ratio
8.4x
EPS (TTM)
$-0.62
Dividend Yield
0.00%
Dilution (1yr)
+7.4%

Why Investors Own EDIT

  • ✓High-growth profile — revenue up +58.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 74% gross margin and 20% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

EDIT logo

EDITAS MEDICINE INC

EDIT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$41M▲ +25.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▼ −119.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$99M▼ −60.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$166M▼ −24.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
88.7M▲ +7.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$70M▼ −$27M YoY
StockOtter · stockotter.space

About EDITAS MEDICINE INC

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$423.38
▲ +10.7% Upside
High Target$527.20
Low Target$327.26
Based on 37 analysts

Latest News & Updates

🚀
Barron’s·2h ago

EDITAS MEDICINE INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift EDIT price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

EDITAS MEDICINE INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.